CDH1 and glioblastoma: It has been demonstrated that activation of the c-Met/AKT/mTOR signaling pathway in GBM upregulates mesenchymal markers, including SNAI1/2, vimentin, and Twist, while concurrently downregulating the epithelial marker E-cadherin [32].